LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2715

Search options

  1. Article: Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond.

    Sano, Motoaki

    Annals of vascular diseases

    2023  Volume 16, Issue 1, Page(s) 8–16

    Abstract: Takayasu's arteritis, first described by Dr. Mikito Takayasu in 1908, is a systemic vasculitis that mostly affects the aorta and its major branches. Although the etiology of the disease is yet unknown, genetic and environmental factors may both play a ... ...

    Abstract Takayasu's arteritis, first described by Dr. Mikito Takayasu in 1908, is a systemic vasculitis that mostly affects the aorta and its major branches. Although the etiology of the disease is yet unknown, genetic and environmental factors may both play a role. One hundred years after the discovery of Takayasu's arteritis, inflammation is finally widely recognized as a fundamental condition common to all vascular diseases, and clinical trials have proven the efficacy of molecularly targeted drugs that block each step of the NLRP3 inflammasome/interleukin (IL)-1β/IL-6 cascade in patients with atherosclerotic vascular disease and elevated C-reactive protein (CRP). Recent advances have also been made in the treatment of Takayasu's arteritis. The randomized controlled trials and subsequent open-label and post-marketing surveillance studies in Japan have demonstrated that tocilizumab, an anti-IL-6 receptor antibody, is effective in the treatment of Takayasu's arteritis and prevents relapse during tapering of prednisolone doses. IL-6 is also heavily engaged in the remodeling of large vessels after acute aortic dissection as demonstrated in animal studies. In patients with acute aortic dissection, those with markedly elevated CRP levels in the acute phase are known to have an increased risk of aorta-related events, such as rupture due to aortic diameter enlargement, in the subacute and chronic phases. We discovered that elevated CRP levels following aortic dissection are caused by IL-6, which is produced by neutrophils that infiltrate the adventitia of the dissected aorta. In a mouse model of acute aortic dissection, we showed that IL-6 produced by these neutrophils causes progressive destruction of the arterial wall structure and that blockade of IL-6 signaling can prevent post-dissection vascular remodeling and improve life outcome. Therefore, inhibiting IL-6 signaling is anticipated to be effective in the secondary prevention of myocardial infarction and suppression of vascular modeling after dissection and even as an anti-inflammatory therapy for Takayasu's arteritis; however, this approach does not solve everything. Undoubtedly, the mechanisms of inflammation in vascular disease are diverse and complex, and the cytokines and cell populations involved at each site (coronary artery vs. aorta) and in each phenotype (atherosclerosis vs. aortic aneurysm vs. aortic dissection) need to be understood for each type of inflammation. Osteopontin (OPN) is a recruiter of monocytes and macrophages, induces cellular immune responses as a Th1 cytokine, acts as a fibrosis-promoting factor, and has been shown to be deeply involved in the pathogenesis of vascular diseases. We have shown that senescent T cells, which emerge with obesity and aging, secrete significant amounts of OPN, leading to metabolic abnormalities and chronic inflammation. Neutrophil extracellular traps (NETs) released from activated neutrophils have been shown to contribute to the pathogenesis of acute coronary syndromes (ACS) by interacting with macrophages, platelets, and vascular endothelial cells and thus promoting plaque erosion and immunothrombosis. In addition to standard anticoagulant and antiplatelet therapies, the effectiveness of anti-immunothrombotic therapies targeting NETs as a new preventive and therapeutic approach for ACS will be examined in the future.
    Language English
    Publishing date 2023-03-10
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 2394256-3
    ISSN 1881-6428 ; 1881-641X
    ISSN (online) 1881-6428
    ISSN 1881-641X
    DOI 10.3400/avd.ra.23-00003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome.

    Sano, Motoaki

    International journal of molecular sciences

    2023  Volume 24, Issue 6

    Abstract: Heart failure, renal dysfunction, anemia, and iron deficiency affect each other and form a vicious cycle, a condition referred to as cardiorenal anemia iron deficiency syndrome. The presence of diabetes further accelerates this vicious cycle. ... ...

    Abstract Heart failure, renal dysfunction, anemia, and iron deficiency affect each other and form a vicious cycle, a condition referred to as cardiorenal anemia iron deficiency syndrome. The presence of diabetes further accelerates this vicious cycle. Surprisingly, simply inhibiting sodium-glucose co-transporter 2 (SGLT2), which is expressed almost exclusively in the proximal tubular epithelial cells of the kidney, not only increases glucose excretion into the urine and effectively controls blood glucose levels in diabetes but can also correct the vicious cycle of cardiorenal anemia iron deficiency syndrome. This review describes how SGLT2 is involved in energy metabolism regulation, hemodynamics (i.e., circulating blood volume and sympathetic nervous system activity), erythropoiesis, iron bioavailability, and inflammatory set points in diabetes, heart failure, and renal dysfunction.
    MeSH term(s) Humans ; Sodium-Glucose Transporter 2/metabolism ; Anemia, Iron-Deficiency/complications ; Anemia, Iron-Deficiency/metabolism ; Anemia/complications ; Anemia/metabolism ; Iron Deficiencies ; Cardio-Renal Syndrome ; Heart Failure/metabolism ; Glucose ; Sodium/metabolism
    Chemical Substances Sodium-Glucose Transporter 2 ; Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27)
    Language English
    Publishing date 2023-03-22
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24065983
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation.

    Sano, Motoaki

    Therapeutic advances in cardiovascular disease

    2020  Volume 14, Page(s) 1753944720939383

    Abstract: This review focuses on the pathogenic role of sodium glucose cotransporter (SGLT)-2 in the development of renal dysfunction and heart failure in patients with diabetes, by emphasizing the concept of reno-cardiac syndrome (kidney injury worsens cardiac ... ...

    Abstract This review focuses on the pathogenic role of sodium glucose cotransporter (SGLT)-2 in the development of renal dysfunction and heart failure in patients with diabetes, by emphasizing the concept of reno-cardiac syndrome (kidney injury worsens cardiac condition) and by substantiating the deleterious effect of sympathetic overdrive in this context. Furthermore, the review proposes a mechanistic hypothesis to explain the benefits of SGLT2 inhibitors, specifically that SGLT-2 inhibitors reduce sympathetic activation at the renal level. To illustrate this point, several examples from both animal experiments and clinical observations are introduced. The bidirectional interaction of the heart and kidney were deeply implicated as an exacerbator of heart failure and renal failure without diabetes. Renal cortical ischemia and abnormal glucose metabolism of tubular epithelial cells are likely to exist as common pathologies in nondiabetic heart failure patients. It is no wonder why SGLT-2 inhibitors are specifically being studied even in the absence of diabetes, both for heart failure and also for renal failure.
    MeSH term(s) Animals ; Cardio-Renal Syndrome/drug therapy ; Cardio-Renal Syndrome/mortality ; Cardio-Renal Syndrome/physiopathology ; Diabetic Nephropathies/drug therapy ; Diabetic Nephropathies/mortality ; Diabetic Nephropathies/physiopathology ; Heart/innervation ; Heart Failure/drug therapy ; Heart Failure/mortality ; Heart Failure/physiopathology ; Humans ; Kidney/innervation ; Risk Factors ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Sympathetic Nervous System/drug effects ; Sympathetic Nervous System/physiopathology ; Treatment Outcome
    Chemical Substances Sodium-Glucose Transporter 2 Inhibitors
    Language English
    Publishing date 2020-07-31
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2485062-7
    ISSN 1753-9455 ; 1753-9447
    ISSN (online) 1753-9455
    ISSN 1753-9447
    DOI 10.1177/1753944720939383
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: A Paradigm Shift in the Treatment of Type 2 Diabetes and Heart Failure.

    Sano, Motoaki

    Journal of atherosclerosis and thrombosis

    2020  Volume 27, Issue 8, Page(s) 727–731

    Abstract: Despite good control of all risk factors for myocardial infarction, including blood glucose, blood pressure, lipids, and smoking, the probability of heart failure is significantly higher in diabetic patients than in healthy individuals. This ... ...

    Abstract Despite good control of all risk factors for myocardial infarction, including blood glucose, blood pressure, lipids, and smoking, the probability of heart failure is significantly higher in diabetic patients than in healthy individuals. This observational study shows that the current treatment guidelines, which focus on the prevention of myocardial infarction, are insufficient in preventing heart failure development. Now, understanding the mechanisms of heart failure in diabetic patients and developing treatment guidelines based on these mechanisms are urgently needed. Instead of narrowly viewing that heart failure is caused by poor cardiac function, we need to take a bird's-eye view that heart failure is caused by a shift in the hemodynamic set point (blood pressure, heart rate, circulating blood volume, and autonomic balance) toward overloading the heart due to the persistent drive of the pathological kidney-brain-heart coupling. Clinical evidence, which shows that sodium-glucose-coupled transporter [Na
    MeSH term(s) Animals ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/metabolism ; Diabetes Mellitus, Type 2/pathology ; Heart Failure/etiology ; Heart Failure/prevention & control ; Humans ; Hypoglycemic Agents/therapeutic use ; Sodium-Glucose Transporter 2/chemistry ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Treatment Outcome
    Chemical Substances Hypoglycemic Agents ; SLC5A2 protein, human ; Sodium-Glucose Transporter 2 ; Sodium-Glucose Transporter 2 Inhibitors
    Language English
    Publishing date 2020-06-26
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 2011474-6
    ISSN 1880-3873 ; 1340-3478
    ISSN (online) 1880-3873
    ISSN 1340-3478
    DOI 10.5551/jat.RV17042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Transthoracic lung biopsy: diagnostic accuracy and complications.

    Sano, Masahiro / Oki, Masahide

    Translational cancer research

    2023  Volume 12, Issue 2, Page(s) 233–235

    Language English
    Publishing date 2023-02-07
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2901601-0
    ISSN 2219-6803 ; 2218-676X
    ISSN (online) 2219-6803
    ISSN 2218-676X
    DOI 10.21037/tcr-22-2703
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity.

    Shirakawa, Kohsuke / Sano, Motoaki

    Frontiers in immunology

    2023  Volume 13, Page(s) 1044737

    Abstract: Obesity has a pronounced effect on the immune response in systemic organs that results in not only insulin resistance but also altered immune responses to infectious diseases and malignant tumors. Obesity-associated microenvironmental changes alter ... ...

    Abstract Obesity has a pronounced effect on the immune response in systemic organs that results in not only insulin resistance but also altered immune responses to infectious diseases and malignant tumors. Obesity-associated microenvironmental changes alter transcriptional expression and metabolism in T cells, leading to alterations in T-cell differentiation, proliferation, function, and survival. Adipokines, cytokines, and lipids derived from obese visceral adipose tissue (VAT) may also contribute to the systemic T-cell phenotype, resulting in obesity-specific pathogenesis. VAT T cells, which have multiple roles in regulating homeostasis and energy utilization and defending against pathogens, are most susceptible to obesity. In particular, many studies have shown that CD4 T cells are deeply involved in the homeostasis of VAT endocrine and metabolic functions and in obesity-related chronic inflammation. In obesity, macrophages and adipocytes in VAT function as antigen-presenting cells and contribute to the obesity-specific CD4 T-cell response by inducing CD4 T-cell proliferation and differentiation into inflammatory effectors
    MeSH term(s) Humans ; CD4-Positive T-Lymphocytes/metabolism ; Intra-Abdominal Fat ; Obesity/metabolism ; Adipocytes/metabolism ; Inflammation
    Language English
    Publishing date 2023-01-04
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.1044737
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?

    Sano, Motoaki

    Internal medicine (Tokyo, Japan)

    2019  Volume 59, Issue 1, Page(s) 1–5

    Abstract: It has become clear that sodium glucose cotransporter (SGLT)-2 inhibitors not only do not increase the incidence of cardiovascular events but they also reduce the duration of hospitalization for heart failure in type 2 diabetes mellitus (T2DM) patients. ... ...

    Abstract It has become clear that sodium glucose cotransporter (SGLT)-2 inhibitors not only do not increase the incidence of cardiovascular events but they also reduce the duration of hospitalization for heart failure in type 2 diabetes mellitus (T2DM) patients. The administration of SGLT2 inhibitor in T2DM patients with hypertension and a fluid retention tendency lowers the blood pressure and mitigates fluid retention. It also reduces the heart rate in T2DM patients with a fast heart rate. As an explanation for the multifaceted effects of SGLT2 inhibitors on hemodynamics, we hypothesize that these agents act on the inter-organ communication pathway, which modulates the sympathetic nerve activity to the cardiovascular system.
    MeSH term(s) Blood Pressure ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/metabolism ; Diabetes Mellitus, Type 2/physiopathology ; Glucose/metabolism ; Heart Failure/metabolism ; Heart Failure/physiopathology ; Hemodynamics ; Humans ; Hypertension/metabolism ; Hypertension/physiopathology ; Kidney/innervation ; Kidney/metabolism ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Stress, Physiological ; Sympathetic Nervous System/metabolism ; Sympathetic Nervous System/physiopathology ; Vasomotor System/physiopathology
    Chemical Substances Sodium-Glucose Transporter 2 Inhibitors ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2019-06-07
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.2870-19
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Helicobacter pylori

    Nishizawa, Toshihiro / Sano, Masaya / Toyoshima, Osamu / Suzuki, Hidekazu

    Journal of clinical medicine

    2024  Volume 13, Issue 3

    Abstract: ... ...

    Abstract Background
    Language English
    Publishing date 2024-02-01
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm13030850
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study.

    Sano, Motoaki

    Circulation reports

    2018  Volume 1, Issue 1, Page(s) 4–7

    Abstract: According to cardiovascular outcome trials, some anti-diabetic drugs can improve cardiovascular outcomes in patients with type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) have a strong ... ...

    Abstract According to cardiovascular outcome trials, some anti-diabetic drugs can improve cardiovascular outcomes in patients with type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) have a strong preventive effect on both hospitalization for heart failure and the decline in kidney function in patients with type 2 diabetes, while glucagon-like peptide-1 receptor agonists, especially human glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and albiglutide), suppress arteriosclerotic diseases (stroke and myocardial infarction). Using these medications in combination could possibly prevent both hospitalization for heart failure and arteriosclerotic events. Dipeptidyl peptidase 4 (DPP-4) inhibitors are preferentially used as add-on therapy for type 2 diabetes. Cardiovascular outcome trials conducted so far suggest that DPP-4 inhibitors (sitagliptin, alogliptin, and saxagliptin) do not promote arteriosclerotic disease, but there may be a difference between these drugs with regard to safety for heart failure. Previous cardiovascular outcome trials have mainly focused on type 2 diabetes patients with established cardiovascular disease. In contrast, the CARMELINA study investigated the cardiovascular safety of linagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes and kidney dysfunction.
    Language English
    Publishing date 2018-12-11
    Publishing country Japan
    Document type Journal Article ; Review
    ISSN 2434-0790
    ISSN (online) 2434-0790
    DOI 10.1253/circrep.CR-18-0011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Advances in geroscience: Cardiovascular disease.

    Sano, Motoaki

    Nihon rinsho. Japanese journal of clinical medicine

    2018  Volume 74, Issue 9, Page(s) 1508–1512

    Abstract: Anti-aging is the ultimate preventive medicine. Delaying the rate of biological aging would simultaneously delay the onset and progression of individual diseases, such as heart disease, cancer, cognitive decline. Laboratory discovery of key mechanisms of ...

    Abstract Anti-aging is the ultimate preventive medicine. Delaying the rate of biological aging would simultaneously delay the onset and progression of individual diseases, such as heart disease, cancer, cognitive decline. Laboratory discovery of key mechanisms of aging and targets of intervention that can modulate aging process is about to translate into clinical application.
    MeSH term(s) Aging ; Biomedical Research ; Cardiovascular Diseases ; Humans
    Language Japanese
    Publishing date 2018-12-17
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 390903-7
    ISSN 0047-1852
    ISSN 0047-1852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top